The MI-mAbs consortium


A chain of expertise unique in the world

As a national priority, Mi-mAbs consortium brings together the entire value chain of immunology and cancer: university, academic research centers, R&D platforms, healthcare institutes and the biopharmaceutical industry.

Prize-Winner of the program « Investments for the Future » 2011 in the "preindustrial demonstrators" category, MI-mAbs was established by Aix-Marseille Université (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC), 3 of their research centers (the Centre d’Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Centre for Immunophenomics), the European leader in immuno-oncology, Innate Pharma and Sanofi, one of the world leaders in health.

Besides its know-how regarding immunotechnology, MI-mAbs also benefits from the complementary expertise of his founders:

  • AMU is the project administrative coordinator.

  • CIML ensures the scientific coordination of Mi-mAbs (under the administrative responsibility of AMU) and offers its expertise in immunology, immunopathology and a wide range of technologies dedicated to antibody production (generation of mouse and rat monoclonal antibodies.)

  • CRCM provides new targets and tumor models for in vitro and in vivo validation

  • IPC gives access to its library of tumors samples

  • CIPHE contributes to the design of in vivo models of the relevant diseases

  • Innate Pharma brings its expertise and experience in monoclonal antibody engineering and immunopharmacology.

  • Sanofi puts at disposal of Mi-mAbs staff and its capacity of production for recombinant proteins, as well as its experience in biological drug development.

In addition, Mi-mAbs will benefit from access to the future inflammatory tissue bank, which will be implemented by the Assistance-Publique Hospitals of Marseille with the support of Marseille Immunopole.

This continuum of expertise brought together in Mi-mAbs is at the heart of the strategy of Marseille Immunopole (MI), the 3rd cluster of the competitive cluster for health Eurobiomed. Its mission: accelerate the development of new immune-based therapies, including monoclonal antibodies, the primary class of drugs in oncology.


Funding & supports